Regulatory Story
Go to market news section View chart   Print
Oxford Technology 2 VCT PLC   -  OXH   

3rd Quarter Results

Released 07:00 17-Dec-2018

3rd Quarter Results


Oxford Technology 2 VCT Plc

Update for the quarter ending 30 November 2018


Oxford Technology 2 VCT Plc presents its quarterly update for the period commencing 1 September 2018. 

The Directors have recently reviewed the valuation of its entire portfolio as at 30 November 2018.

The unaudited net asset value per ordinary share (NAV) as at 30 November 2018 was 30.2p.  This is a fall of 0.2p from the previously published NAV for the period ending 31 August 2018. The decrease in NAV was primarily due to a fall in the bid price of Scancell (11.5p at 31 August 2018 to 7.8p). An investment of £59k was also made in the period in Orthogem at a slightly increased valuation.

The total return to shareholders including previous dividends of 21.0p per share is now 51.2p per share.

The total number of ordinary shares in issue is 5,331,889.

On 19 November 2018, Shareholders overwhelmingly supported the Board’s proposals to enlarge the Company’s share capital. The Directors continue to work actively with Chelverton Asset Management and their advisers on an offer for subscription of a new class of shares and hope to be able to publish the required prospectus in the near future.

The Directors are not aware of any other events or transactions which have taken place between 30 November 2018 and the publication of this statement which have had a material effect on the financial position of the Company.

17 December 2018

Enquiries:
Lucius Cary, Oxford Technology Management
01865 784466



Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


3rd Quarter Results - RNS